Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of rocatinlimab in adults with moderate to severe asthma
CTR20242724Phase 2Terminated
- Sponsor
- Amgen
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of rocatinlimab in asthma, sponsored by Amgen. Started Jul 2024; status: terminated.
02
Drugs
rocatinlimab
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20242724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242724.